SCHEMBL1750878

SCHEMBL1750878

CCC(=O)NCc1ccc(Cl)c(C=O)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
TRPV1 Q8NER1 1/20 0.43
HPGD P15428 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP3A4 P08684 2/20 0.42
P2RX7 Q99572 3/20 0.41
ERCC1 P07992 3/20 0.41
ERCC4 Q92889 3/20 0.41
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750145 0.85 TSHR (0.50) TSHRSMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL1751039 0.84 TSHR (0.69) TSHRSMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL30259914 0.83 TSHR (0.68) TSHRSMN1; SMN2TRPV1HPGDALDH1A1
SCHEMBL6361222 0.83 TSHR (0.68) TSHRSMN1; SMN2TRPV1HPGDALDH1A1
SCHEMBL1751145 0.82 TSHR (0.41) TSHRSMN1; SMN2TRPV1HPGDP2RX7
SCHEMBL16670980 0.81 PTGES (0.49) TSHRSMN1; SMN2HPGD
SCHEMBL16671183 0.81 ERCC1 (0.56) TSHRERCC1ERCC4
SCHEMBL1751352 0.80 ERCC1 (0.51) SMN1; SMN2HPGDALDH1A1P2RX7ERCC1
SCHEMBL1750408 0.79 TSHR (0.50) TSHRSMN1; SMN2TRPV1HPGDALDH1A1
SCHEMBL29952190 0.78 TSHR (0.54) TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968720-B2 Secondary amines as renin inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2011-06-28 US disclosed
US-20090176823-A1 Secondary Amines as Renin Inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176823-A1 Secondary Amines as Renin Inhibitors REN, ACE, AGTR1 TSHR 1994/4885SMN1; SMN2 4441/4885TRPV1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.